Lead Product(s): SO-N102
Therapeutic Area: Oncology Product Name: SOT102
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
SOT102 demonstrated favorable tolerability and pharmacokinetic properties, with the latter substantiated by observed half-lives in the range of eight days and 13 days in cynomolgus monkey and rat, respectively.